Treatment of HCV disorders

Details for Australian Patent Application No. 2006204524 (hide)

Owner Novartis AG

Inventors Brinkmann, Volker; Feutren, Gilles

Agent Davies Collison Cave

Pub. Number AU-B-2006204524

PCT Pub. Number WO2006/072562

Priority 0500020.3 04.01.05 GB

Filing date 2 January 2006

Wipo publication date 13 July 2006

Acceptance publication date 27 May 2010

International Classifications

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61K 31/381 (2006.01) - having five-membered rings

A61K 31/397 (2006.01) - having four-membered rings, e.g. azetidine

A61K 31/661 (2006.01) - Phosphorus acids or esters thereof not having PC bonds, e.g. fosfosal, dichlorvos, malathion

A61P 31/14 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Event Publications

21 June 2007 PCT application entered the National Phase

  PCT publication WO2006/072562 Priority application(s): WO2006/072562

27 May 2010 Application Accepted

  Published as AU-B-2006204524

23 September 2010 Standard Patent Sealed

23 September 2010 Corrigenda

  Applications Accepted - Name Index Under the name Novartis AG, Application No. 2006204524, under INID (32) correct the date to 04.01.05

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006204528-Use of compounds involved in biosynthesis of nucleic acids to increase yield of bacterial cultures

2006204523-X-ray structure of human FPPS and use for selecting FPPS binding compounds